BMY-28142与其他β-内酰胺类抗菌剂相比的体外活性。
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
作者信息
Tsuji A, Maniatis A, Bertram M A, Young L S
出版信息
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
Abstract
The in vitro susceptibility of 406 clinical isolates to BMY-28142, a new semisynthetic cephem, was evaluated and compared with cefpimizole, HR 810, ceftazidime, cefotaxime, moxalactam, and cefoperazone in a broth microdilution assay. On a weight basis, the activity of BMY-28142 against Escherichia coli, Proteus species, and Klebsiella-Enterobacter-Serratia was superior to the other cephems. Against gentamicin-susceptible and -resistant Pseudomonas aeruginosa, BMY-28142 was more active than the other cephems, except ceftazidime and HR 810. A total of 74% of gram-negative and 56% of gram-positive isolates resistant to third-generation cephalosporins were susceptible to less than or equal to 8 micrograms of BMY-28142 per ml. Finally, for 83% of tested isolates, the bactericidal concentration of BMY-28142 was within one dilution of the inhibitory concentration.
摘要
采用肉汤微量稀释法，对406株临床分离菌株对新型半合成头孢菌素BMY-28142的体外敏感性进行了评估，并与头孢咪唑、HR 810、头孢他啶、头孢噻肟、拉氧头孢和头孢哌酮进行了比较。以重量计，BMY-28142对大肠杆菌、变形杆菌属以及克雷伯菌-肠杆菌-沙雷菌属的活性优于其他头孢菌素。对于对庆大霉素敏感和耐药的铜绿假单胞菌，BMY-28142比其他头孢菌素更具活性，但头孢他啶和HR 810除外。总共74%的对第三代头孢菌素耐药的革兰阴性菌和56%的革兰阳性菌分离株对每毫升小于或等于8微克的BMY-28142敏感。最后，对于83%的测试分离株，BMY-28142的杀菌浓度在抑菌浓度的一个稀释度范围内。
相似文献
1
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
2
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
3
Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
Antimicrob Agents Chemother. 1985 Feb;27(2):207-16. doi: 10.1128/AAC.27.2.207.
4
Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Diagn Microbiol Infect Dis. 1999 Oct;35(2):135-42. doi: 10.1016/s0732-8893(99)00061-9.
5
The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
J Antimicrob Chemother. 1986 Apr;17(4):441-52. doi: 10.1093/jac/17.4.441.
6
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x.
7
Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
Pathology. 1987 Jul;19(3):274-6. doi: 10.3109/00313028709066562.
8
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.
Diagn Microbiol Infect Dis. 1986 Nov;5(4):345-9. doi: 10.1016/0732-8893(86)90041-6.
9
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Diagn Microbiol Infect Dis. 1997 Dec;29(4):265-72. doi: 10.1016/s0732-8893(97)00157-0.
10
In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Diagn Microbiol Infect Dis. 1999 Dec;35(4):285-90. doi: 10.1016/s0732-8893(99)00099-1.
引用本文的文献
1
Comparative activity of cefepime with several antimicrobials against aerobic Gram-negative and Gram-positive organisms isolated from patients across Canada in 1993.
Can J Infect Dis. 1995 Sep;6(5):258-62. doi: 10.1155/1995/458762.
2
In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.
Can J Infect Dis. 1999 Mar;10(2):122-7. doi: 10.1155/1999/172031.
3
Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.
Folia Microbiol (Praha). 2009 Sep;54(5):391-4. doi: 10.1007/s12223-009-0054-1. Epub 2009 Nov 24.
4
SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.
J Clin Microbiol. 2005 Oct;43(10):5058-64. doi: 10.1128/JCM.43.10.5058-5064.2005.
5
In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
Antimicrob Agents Chemother. 2003 Aug;47(8):2507-12. doi: 10.1128/AAC.47.8.2507-2512.2003.
6
Cefepime clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Aug;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
7
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.
Antimicrob Agents Chemother. 1994 Mar;38(3):415-21. doi: 10.1128/AAC.38.3.415.
8
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.
9
Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
J Clin Microbiol. 1986 Mar;23(3):634-6. doi: 10.1128/jcm.23.3.634-636.1986.
10
Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.
Antimicrob Agents Chemother. 1987 May;31(5):799-804. doi: 10.1128/AAC.31.5.799.
本文引用的文献
1
Bactericidal activity of cefazolin, cefoxitin, and cefmetazole against Escherichia coli and Klebsiella pneumoniae.
Chemotherapy. 1982;28(1):18-25. doi: 10.1159/000238056.
2
The new beta-lactamase-stable cephalosporins.
Ann Intern Med. 1982 Sep;97(3):408-19. doi: 10.7326/0003-4819-97-3-408.
3
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.
Antimicrob Agents Chemother. 1984 Jun;25(6):710-8. doi: 10.1128/AAC.25.6.710.
4
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.
Antimicrob Agents Chemother. 1983 Sep;24(3):375-82. doi: 10.1128/AAC.24.3.375.
5
In vitro activity of HR 810, a new cephalosporin.
Antimicrob Agents Chemother. 1984 Aug;26(2):277-9. doi: 10.1128/AAC.26.2.277.
6
Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.
Antimicrob Agents Chemother. 1984 Oct;26(4):585-90. doi: 10.1128/AAC.26.4.585.
7
Clinical use of the new beta-lactam antimicrobial drugs. Practical considerations for physicians, microbiology laboratories, pharmacists, and formulary committees.
Ann Intern Med. 1983 Apr;98(4):530-5. doi: 10.7326/0003-4819-98-4-530.
8
Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.
Eur J Clin Microbiol. 1983 Aug;2(4):350-2. doi: 10.1007/BF02019466.
9
The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever.
J Antimicrob Chemother. 1981 Jul;8(1):23-8. doi: 10.1093/jac/8.1.23.
10
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
Antimicrob Agents Chemother. 1980 Oct;18(4):645-8. doi: 10.1128/AAC.18.4.645.
Zotero 插件